Abstract: The invention concerns a novel nogamycin having a heretofore unknown configuration and novel analogs which are active against various microorganisms. The invention also includes novel methods of making substituted and unsubstituted nogamycin having an essentially pure isomeric form of a preferred configuration.

Abstract: Novel and useful compounds are obtained by the degradation of antibiotics paulomycin A and paulomycin B. These novel compounds are useful as ultraviolet light filters in plastics, cloth, and the like.

Abstract: Novel and useful antibiotics designated 273a.sub.1.spsb..alpha. and 273a.sub.1.spsb..beta. can be produced in a fermentation using Streptomyces paulus, strain 273, NRRL 12251. These antibiotics are active against various Gram-positive bacteria. Also, these antibiotics are, advantageously, soluble in aqueous solutions.

Abstract: Novel N-demethyl derivatives of nogalamycin and process for preparing the same. The compounds of this invention are active against various microorganisms.

Abstract: Novel regioselective acylates of the antibiotic nogalamycin and its dimethylamino-retaining analogs are prepared by a selective acylation procedure. The compounds of the invention have antibacterial activity, and, thus, can be used in various environments to control or eradicate susceptible bacteria.

Abstract: Photochemical process for preparing N-demethyl-derivatives of nogalamycin.

Abstract: New antibiotic U-53,946 produced by the controlled fermentation of the new microorganism Paecilomyces abruptus sp. nov., NRRL 11110. This antibiotic is active against Gram-positive bacteria, for example, Sarcina lutea, Staphylococcus aureus, Bacillus subtilis, Mycobacterium avium, and Streptococcus pyogenes, and the yeast Saccharomyces pastorianus. Accordingly, they can be used in various environments to eradicate or control these microorganisms.

Abstract: Antibiotics 10-dihydrosteffimycin (U-58,875), and 10-dihydrosteffimycin B (U-58,874) are produced by carbon 10 ketonic carbonyl reduction in fermentation processes using the known antibiotics steffimycin and steffimycin B, respectively, as starting materials. These novel antibiotics are active against various microorganisms, for example, Bacillus subtilis, Bacillus cereus, Sarcina lutea, Streptococcus pyogenes, and Mycobacterium avium. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: Novel antibiotics, 7(R)-0-alkylnogalarols, prepared by acidic alcoholysis of nogalamycin of nogalarol, which are active against various microorganisms, for example, Bacillus subtilis, Streptococcus pyogenes, Sarcina lutea, Bacteroides fragilis, Clostridium perfringens, and Mycobacterium avium. Thus, they can be used to inhibit the growth of the above microorganisms in various environments. Further, the invention compounds possess unexpected superior activity against P388 leukemia infection in laboratory mice. Thus, the compounds of the invention can be used to treat laboratory mice infected with P388 leukemia.

Abstract: Antibiotics 10-dihydrosteffimycin (U-58,875), and 10-dihydrosteffimycin B (U-58,874) are produced by carbon 10 ketonic carbonyl reduction in fermentation processes using the known antibiotics steffimycin and steffimycin B, respectively, as starting materials. These novel antibiotics are active against various microorganisms, for example, Bacillus subtilis, Bacillus cereus, Sarcina lutea, Streptococcus pyogenes, and Mycobacterium avium. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: Novel antibiotics, 7(S)--O--alkylnogarols, prepared by acidic alcoholysis of nogamycin, which are active against various microorganisms, for example, Bacillus subtilis, Streptococcus pyogenes, and Mycobacterium avium. Thus, they can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: New antiobiotic U-53,946 produced by the controlled fermentation of the new microorganism Paecilomyces abruptus sp. nov., NRRL 11110. This antibiotic is active against Gram-positive bacteria, for example, Sarcina lutea, Staphylococcus aureus, Bacillus subtilis, Mycobacterium avium, and Streptococcus pyrogenes, and the yeast Saccharomyces pastorianus. Accordingly, they can be used in various environments to eradicate or control these microorganisms.

Abstract: Bioconversion of the antibiotic steffimycinone to the antibiotic steffimycinol. Steffimycinol is active against various microorganisms, for example, Bacillus subtilis, Mycobacterium avium and Streptococcus pyogenes. Steffimycinol is converted to 7-deoxysteffimycinol by a microaerophilic Aeromonas hydrophila fermentation. 7-Deoxysteffimycinol is active against Sarcina lutea, Bacillus cereus, and B. subtilis. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: Bioconversion of the antibiotic steffimycinone to the antibiotic steffimycinol. Steffimycinol is active against various microorganisms, for example, Bacillus subtilis, Mycobacterium avium and Streptococcus pyogenes. Steffimycinol is converted to 7-deoxysteffimycinol by a microaerophilic Aeromonas hydrophila fermentation. 7-Deoxysteffimycinol is active against Sarcina lutea, Bacillus cereus, and B. subtilis. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: Antibiotics steffimycinol and 7-deoxysteffimycinol produced by reduction of the antibiotic steffimycinone. Steffimycinol is active against various microorganisms, for example, Bacillus subtilis, Mycobacterium avium and Streptococcus pyogenes; 7-deoxysteffimycinol is active against Sarcina lutea, Bacillus cereus, and B. subtilis. Thus, these antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: Novel antibiotics, 7-O-alkylnogarols, prepared by acidic alcoholysis of nogamycin, which are active against various microorganisms, for example, Bacillus subtilis and Lactobacillus casei. Thus, they can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: Bioconversion of the antibiotic steffimycinone to the antibiotic steffimycinol. Steffimycinol is active against various microorganisms, for example, Bacillus subtilis, Mycobacterium avium and Streptococcus pyogenes. Steffimycinol is converted to 7-deoxysteffimycinol by a microaerophilic Aeromonas hydrophila fermentation. 7-Deoxysteffimycinol is active against Sarcina lutea, Bacillus cereus, and B. subtilis. Thus, there antibiotics can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: Novel antibiotic, nogalamycinic acid (U-51,205) prepared by the chemical modification of the known antibiotic nogalamycin. Nogalamycinic acid is active against various microorganisms, for example, Mycobacterium avium, Bacillus subtilis, Lactobacillus casei, Staphylococcus aureus, and Sarcina lutea. Thus, nogalamycinic acid can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: Novel antibiotic, nogamycin (U-51,204) prepared chemically from nogalamycinic acid. Nogamycin is active against various microorganisms, for example, Mycobacterium avium, Bacillus subtilis, Lactobacillus casei, Staphylococcus aureus, and Sarcina lutea. Thus, nogamycin can be used to inhibit the growth of the above microorganisms in various environments.

Abstract: New antibiotic U-43,120 producible by the controlled fermentation of the new microorganism Streptomyces paulus, NRRL 8115.This antibiotic is active against Gram-positive and Gram-negative bacteria. Accordingly, it can be used in various environments to eradicate or control such bacteria.